ArticleBMC genomics2018
Integration of multiple networks and pathways identifies cancer driver genes in pan-cancer analysis.
Article in BMC genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- In-silico analysis of multi-pathway crosstalk inhibition of santamarin in hepatocellular carcinoma.Journal of molecular histology · 2026Article
- KAT2A: a prognostic biomarker influencing proliferation and immune escape in lung adenocarcinoma.BMC cancer · 2025Article
- Deep profiling of gene expression across 18 human cancers.Nature biomedical engineering · 2025Article
- A deep profile of gene expression across 18 human cancers.bioRxiv : the preprint server for biology · 2024Article
- ECD-CDGI: An efficient energy-constrained diffusion model for cancer driver gene identification.PLoS computational biology · 2024Article
- Children's Oncology Group's 2023 blueprint for research: Germ cell tumors.Pediatric blood & cancer · 2023Article
- Article
- Immunotherapeutic Value of MAP1LC3C and Its Candidate FDA-Approved Drugs Identified by Pan-Cancer Analysis, Virtual Screening and Sensitivity Analysis.Frontiers in pharmacology · 2022Article
- Combining bioinformatics, network pharmacology and artificial intelligence to predict the mechanism of celastrol in the treatment of type 2 diabetes.Frontiers in endocrinology · 2022Article
- An integrated pan-cancer analysis of TFAP4 aberrations and the potential clinical implications for cancer immunity.Journal of cellular and molecular medicine · 2021Article
- Application of Immune Infiltration Signature and Machine Learning Model in the Differential Diagnosis and Prognosis of Bone-Related Malignancies.Frontiers in cell and developmental biology · 2021Article
- Analysis of the PD-1 Ligands Among Gastrointestinal Cancer Patients: Focus on Cancer Immunity.Frontiers in oncology · 2021Article
- Four Novel Prognostic Genes Related to Prostate Cancer Identified Using Co-expression Structure Network Analysis.Frontiers in genetics · 2021Article
- DORGE: Discovery of Oncogenes and tumoR suppressor genes using Genetic and Epigenetic features.Science advances · 2020Article
- Pan-cancer mapping of differential protein-protein interactions.Scientific reports · 2020Article
- Multi-Approach Bioinformatics Analysis of Curated Omics Data Provides a Gene Expression Panorama for Multiple Cancer Types.Frontiers in genetics · 2020Article
- Theranostic application ofTheranostics · 2020Article
- NCAPG Is a Promising Therapeutic Target Across Different Tumor Types.Frontiers in pharmacology · 2020Article
- Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study.Frontiers in immunology · 2020Article
- Screening of differential expressed genes from gene chip and sequencing data and evaluate its prognostic values in males with digestive system neoplasms.Translational cancer research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundModern high-throughput genomic technologies represent a comprehensive hallmark of molecular changes in pan-cancer studies. Although different cancer gene signatures have been revealed, the mechanism of tumourigenesis has yet to be completely understood. Pathways and networks are important tools to explain the role of genes in functional genomic studies. However, few methods consider the functional non-equal roles of genes in pathways and the complex gene-gene interactions in a network.
resultsWe present a novel method in pan-cancer analysis that identifies de-regulated genes with a functional role by integrating pathway and network data. A pan-cancer analysis of 7158 tumour/normal samples from 16 cancer types identified 895 genes with a central role in pathways and de-regulated in cancer. Comparing our approach with 15 current tools that identify cancer driver genes, we found that 35.6% of the 895 genes identified by our method have been found as cancer driver genes with at least 2/15 tools. Finally, we applied a machine learning algorithm on 16 independent GEO cancer datasets to validate the diagnostic role of cancer driver genes for each cancer. We obtained a list of the top-ten cancer driver genes for each cancer considered in this study.
conclusionsOur analysis 1) confirmed that there are several known cancer driver genes in common among different types of cancer, 2) highlighted that cancer driver genes are able to regulate crucial pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.